Cybin CEO to Present Psychedelic Therapy Developments at Growth Conference

Cybin Inc. CEO Doug Drysdale will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston. The presentation will focus on Cybin's pioneering work in neuropsychiatry and the development of psychedelic-based therapies for mental health conditions. This discussion comes at a critical time as mental health disorders continue to affect millions worldwide, creating significant unmet needs in healthcare that current treatments often fail to adequately address.

The webcast presentation, scheduled for 2:30 p.m. ET, will provide detailed insights into Cybin's clinical-stage compounds CYB003 and CYB004. These proprietary molecules represent the company's innovative approach to mental health treatment, with CYB003 being studied for major depressive disorder and CYB004 targeting generalized anxiety disorder. The company's research strategy emphasizes intermittent treatments designed to deliver long-lasting results, marking a significant departure from traditional daily medications that many patients find insufficient or burdensome.

Cybin's commitment to advancing psychedelic science is demonstrated through its robust pipeline of investigational compounds that target 5-HT receptors, which play a crucial role in mood regulation. This scientific approach represents a paradigm shift in mental health treatment, offering potential solutions for individuals who have not responded adequately to existing therapies. The archived webcast will remain accessible through Cybin's investor relations site at https://www.cybin.com/investors, providing ongoing access to this important discussion about the future of mental health treatment.

The participation of Cybin's leadership at this prominent growth conference underscores the increasing recognition of psychedelic-based therapies as a viable and promising avenue for mental health treatment. As the company advances its clinical programs, the potential for these innovative treatments to make meaningful differences in patients' lives becomes more tangible. This development represents a significant step forward in addressing the global mental health crisis through novel therapeutic approaches that could transform treatment standards and outcomes for millions suffering from these debilitating conditions.